| Child's Name:   | Birthdate:   |  |  | Male/Female   | School                               | l:   |
|---|--|--|--|---|--------------------------------------|--|
| Last,   | FIRST  | First month/da   |  |   |                                      |  |
| AddressStreet   | City   | Z  | р  | Phone:  |                                      | Grade:   |
|   | •  |  | •  |   |                                      |  |
| Santa Clara County Public Health Department   |  |  |  |   |                                      |  |
| Tuberculosis (TB) Risk Assessment for School Entry  |  |  |  |   |                                      |  |
| This form must be comp  | leted by a licensed h  | nealth prof  | essi   | ional in the U.S. and   | returne                              | d to the child's school.   |
| 1. Was your child born in, resided, or traveled (for more that country with an elevated rate of TB*?  |  |  |  | one month) to a   | <b>-</b>                             | Yes □ No   |
| 2. Has your child been in close contact to anyone with tuberculosis (TB) disease in their lifetime?   |  |  |  |   |                                      | Yes □ No   |
| 3. Is your child immunosuppressed; current, or planned? (e.g., due to HIV infection, organ transplant, treatment with TNF-alpha antagonist or high-dose systemic  |  |  |  |   |                                      |  |
| *Most countries other than the U.S., Canada, Australia, New Zealand, or a country in western or northern Europe. This does not include tourist travel for <1 month (i.e., travel that does not involve visiting family or friends, or involve significant contact with the local population).   |  |  |  |   |                                      |  |
| If YES, to any of the above questions, the child has an increased risk of TB and should have a TB blood test (IGRA, i.e. QuantiFERON or T-SPOT.TB) or a tuberculin skin test (TST) unless there is either 1) a documented prior positive IGRA or TST performed in the U.S. or 2) no new risk factors since last documented negative IGRA (performed at age ≥2 years in the U.S.) or TST (performed at age ≥6 months in the U.S.). |  |  |  |   |                                      |  |
| normal, the child should b  | nd lateral for children<br>nt for TB disease, doo<br>ive TST and negative<br>e treated for latent TB | <5 years ol<br>umented p<br>IGRA. If the<br>infection (I | d is<br>rior t<br>ere a<br>-TBI                        | recommended). CXR<br>treatment for latent TE<br>are no symptoms or si<br>) to prevent progression | is not re<br>3 infection<br>gns of T | equired for children with<br>on, or BCG-vaccinated<br>B disease and the CXR is |
| Enter test results for all  | •  | ive risk as  | ses  | sment:  |                                      |  |
| Interferon Gamma Relea  | ise Assay (IGRA)   |  | Do   | oult: 🗖 Nogotivo 🔲  | Dogitiv                              | a D Indotorminata  |
| Date:   |  |  | Result: Negative Positive Indeterminate  Induration mm |   |                                      |  |
| Tuberculin Skin Test (TST/Mantoux/PPD)  |  |  | Result:   Negative Positive                            |   |                                      |  |
| Date placed:  | Date read:   | □ Nava   |  |   | Positive                             | <del>8</del>   |
| Chest X-Ray Date: LTBI Treatment Start Da   | •  | on: 🗖 Norn   |  | ☐ Abnormal  Prior TB/LTBI treatm  | ent (Rv                              | & duration):   |
| ☐ Rifampin da   | ily - 4 months   |  |  |   |                                      | <u>,</u>   |
|   | apentine - weekly X 1<br>ily - 9 months  | 2 weeks  |  | Treatment medically   | contrain                             | ndicated   |
| Other:  |  |  |  | Declined against me   | dical adv                            | vice   |
| ☐ Child has a risk factor   | boxes below and sign<br>optoms, no risk factors<br>or, has been evaluated<br>k factors since last ne | for TB, and<br>I for TB and                              | l is f   | ree of active TB disea  | se.                                  |  |
|   |  | Health C   | are I  | Provider Signature, Title   |                                      | Date   |
| Name/Title of Health Pro<br>License Number:<br>Facility/Address:<br>Phone number:   | vider:   |  |  |   |                                      |  |

## County of Santa Clara

**Public Health Department** 

Tuberculosis Prevention & Control Program 976 Lenzen Avenue, Suite 1700 San José, CA 95126 408.885.2440



## **Testing Methods**

An Interferon Gamma Release Assay (IGRA, i.e., QuantiFERON or T-SPOT.TB) or Mantoux tuberculin skin test (TST) should be used to test those at increased risk. An IGRA can be used in all children  $\geq$  2 years old and is preferred in BCG-vaccinated children to avoid a false positive TST result. A TST of  $\geq$ 10mm induration is considered positive. If a child has had contact with someone with active TB disease (yes to question 2 on reverse), or the child is immunosuppressed, then TST  $\geq$ 5 mm is considered positive. If a BCG-vaccinated child has a positive TST, and an IGRA is subsequently performed and is negative, testing is considered negative unless the child was exposed to someone with TB disease or is immunosuppressed. For immunosuppressed children, screening should be performed by CXR in addition to a TST/IGRA (consider doing both) and symptom review. TB screening can be falsely negative within 8 weeks after exposure, so are best obtained 8 weeks after last exposure.

## **Evaluation of Children with Positive TB Tests**

- All children with a positive IGRA/TST result must have a medical evaluation, including a CXR (posterior-anterior
  and lateral is recommended for children <5 years old). A CXR is not required for a positive TST with negative
  IGRA in a BCG-vaccinated child, or if the child has documentation of prior treatment for TB disease or treatment
  for latent TB infection.</li>
- For children with TB symptoms (e.g., cough for >2-3 weeks, shortness of breath, hemoptysis, fever, weight loss, night sweats) or an abnormal CXR consistent with active TB disease, report to the County of Santa Clara Public Health Department TB Program within one day. The child will need to be evaluated for TB disease with sputum AFB smears/cultures and nucleic acid amplification testing. A negative TST or IGRA does not rule out active TB disease in a patient with symptoms or signs of TB disease. The child cannot enter school unless active TB disease has been excluded or treatment has been initiated.
- If there are no symptoms or signs of TB disease and the CXR is normal, the child should be treated for latent TB infection (LTBI). Do not treat for LTBI until active TB disease has been excluded.
- Short-course regimens (rifampin daily for four months or 12-dose weekly isoniazid/rifapentine) are preferred (except in persons for whom there is a contraindication, such as a drug interaction or contact to a person with drug-resistant TB) due to similar efficacy and higher treatment completion rates as compared with 9 months of daily isoniazid.

## **Treatment Regimens for Latent TB Infection**

- Rifampin 15 20 mg/kg (max. 600 mg) daily for 4 months
- 12-dose Weekly Isoniazid/Rifapentine (3HP) Regimen:
  - Isoniazid

2-11 years old: 25 mg/kg rounded up to nearest 50 or 100 mg (max. 900 mg) ≥ 12 years old: 15 mg/kg rounded up to nearest 50 or 100 mg (max. 900 mg)

Rifapentine

10.0-14.0 kg: 300 mg 14.1-25.0 kg: 450 mg 25.1-32.0 kg: 600 mg 32.1-50.0 kg: 750 mg

>50 kg: 900 mg

- Vitamin B6 50 mg weekly
- Isoniazid 10 mg/kg (range, 10-15 mg/kg; max. 300 mg) daily for 9 months. Recommended pyridoxine dosage is 25 mg for school-aged children (or 1-2 mg/kg/day).

Board of Supervisors: Mike Wasserman, Cindy Chavez, Otto Lee, Susan Ellenberg, S. Joseph Simitian, County Executive: Jeffrey V. Smith